Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms

Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of hematologic malignancies. We investigated the effic...

Full description

Bibliographic Details
Main Authors: Paola Circosta, Angela Rita Elia, Indira Landra, Rodolfo Machiorlatti, Maria Todaro, Sabrina Aliberti, Davide Brusa, Silvia Deaglio, Sabina Chiaretti, Riccardo Bruna, Daniela Gottardi, Massimo Massaia, Filomena Di Giacomo, Anna Rita Guarini, Robin Foà, Peter W. Kyriakides, Rohan Bareja, Olivier Elemento, Gurunadh R. Chichili, Emanuele Monteleone, Paul A. Moore, Syd Johnson, Ezio Bonvini, Alessandro Cignetti, Giorgio Inghirami
Format: Article
Language:English
Published: Taylor & Francis Group 2018-04-01
Series:OncoImmunology
Subjects:
b-cell malignancies
bispecific antibodies
cik cells
dart cd19xcd3
pdtx
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1341032

Internet

http://dx.doi.org/10.1080/2162402X.2017.1341032

Similar Items